

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

Ophidian Pharmaceuticals, Inc.  
-----

(Name of Issuer)

Common Stock, \$.0025 Par Value  
-----

(Title of Class of Securities)

683725105  
-----

(CUSIP Number)

October 5, 1999  
-----

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this  
Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

---

\*The remainder of this cover page shall be filled out for a reporting  
person's initial filing on this form with respect to the subject class of  
securities, and for any subsequent amendment containing information which  
would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be  
deemed to be "filed" for the purpose of Section 18 of the Securities  
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of  
that section of the Act but shall be subject to all other provisions of the  
Act (however, see the Notes).

CUSIP No. 683725105

(1) Name of Reporting Person: I.R.S. Identification No. of Above Person	Eli Lilly and Company 35-0470950
(2) Check the Appropriate Box if a Member of a Group	(a) [ ] (b) [ ] Not Applicable
(3) SEC Use Only	
(4) Citizenship or Place of Organization	Indiana
Number of Shares Beneficially Owned by Each Reporting Person With	(5) Sole Voting Power 74,412 (6) Shared Voting Power None (7) Sole Dispositive Power 74,412 (8) Shared Disposi- tive Power None
(9) Aggregate Amount Beneficially Owned by Each Reporting Person	74,412
(10) Check if the Aggregate Amount In Row (9) Excludes Certain Shares	Not Applicable
(11) Percent of Class Represented by Amount in Row (9)	6.4%
(12) Type of Reporting Person	C0

- Item 1(a). Name of Issuer:  
Ophidian Pharmaceuticals, Inc.
- Item 1(b). Address of Issuer's Principal Executive Offices:  
5445 East Cheryl Parkway  
Madison, WI 53711
- Item 2(a). Name of Person Filing:  
Eli Lilly and Company
- Item 2(b). Address of Principal Business Office or, if None, Residence:  
Lilly Corporate Center  
Indianapolis, IN 46285
- Item 2(c). Citizenship:  
Indiana
- Item 2(d). Title of Class of Securities:  
Common Stock, \$.0025 Par Value
- Item 2(e). CUSIP Number:  
683725105
- Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:  
(a)-(j) Not applicable  
If this statement is filed pursuant to Rule 13d-1(c), check this box. [ ]

Item 4.            Ownership.

          (a) Amount Beneficially Owned:

                  74,412

          (b) Percent of Class:

                  6.4%

          (c) Number of shares as to which the person has:

Sole voting power	74,412
Shared voting power	None
Sole dispositive power	74,412
Shared dispositive power	None

Item 5.            Ownership of Five Percent or Less of a Class.

          Not applicable

Item 6.            Ownership of More Than Five Percent on Behalf of Another Person.

          Not applicable

Item 7.            Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

          Not applicable

Item 8.            Identification and Classification of Members of the Group.

          Not applicable

Item 9.            Notice of Dissolution of Group.

          Not applicable

Item 10. Certifications.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ELI LILLY AND COMPANY

By: \_\_\_\_\_  
Charles E. Golden  
Executive Vice President and  
Chief Financial Officer

Date: February 10, 2000